Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,760.00+1.42%ETH$2,459.67+2.60%GOLD$4,413.80+0.60%OIL$99.75-2.62%
Smart Investors Daily
BeyondSpring Inc. logo

NASDAQ · BYSI

BeyondSpring Inc.

Healthcare · Biotechnology

$0.71

Down-$0.04 (-5.56%)

Updated Sep 17, 2026, 1:08 PM

SID Score

2.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
88.73M
P/E ratio
43.69
Dividend yield
0.00%
52-week range
$0.57 – $1.92
Volume
35.66K
Avg. volume
35.87K

Price performance

BYSI price history

1M range · 20 trading sessions · Daily adjusted prices

BYSI closed at $0.71 after 20 trading sessions, down 1.83% for the selected period.

Last close
$0.71
Period change
-1.83%
Period low
$0.60
Period high
$0.77
Daily close
View OHLC price history
BYSI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$0.7367$0.7609$0.701$0.708835.66K
Sep 15, 2026$0.7373$0.7999$0.7373$0.750518.9K
Sep 14, 2026$0.753$0.7893$0.747$0.7630.91K
Sep 11, 2026$0.7786$0.7794$0.711$0.76495.11K
Sep 10, 2026$0.6085$0.79$0.6085$0.7668846.54K
Sep 9, 2026$0.62$0.63$0.6051$0.628740.11K
Sep 8, 2026$0.6222$0.6318$0.6043$0.620231.01K
Sep 4, 2026$0.628$0.6477$0.60$0.618126.91K
Sep 3, 2026$0.641$0.6499$0.6221$0.622243.68K
Sep 2, 2026$0.6027$0.6481$0.6027$0.61140.32K
Sep 1, 2026$0.608$0.6489$0.6002$0.602653.16K
Aug 31, 2026$0.639$0.6625$0.6122$0.620555.84K
Aug 28, 2026$0.61$0.6699$0.61$0.6654114.24K
Aug 27, 2026$0.6824$0.6957$0.5657$0.6402297.2K
Aug 26, 2026$0.7002$0.7201$0.688$0.6935.17K
Aug 25, 2026$0.71$0.7744$0.71$0.720244.41K
Aug 24, 2026$0.7003$0.7224$0.7002$0.709226.92K
Aug 21, 2026$0.72$0.7451$0.7002$0.720159.43K
Aug 20, 2026$0.70$0.7634$0.70$0.720136.09K
Aug 19, 2026$0.72$0.79$0.70$0.722155.46K

Latest BYSI news

The latest Smart Investors Daily articles mentioning BYSI.

Stock researchCompany · Overview

BYSI research

Overview

Company profile and research snapshot.

Company profile

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BYSI recent ratings
DateFirmRatingTarget
May 2, 2023BairdOutperform—
Dec 2, 2021JefferiesHold—
Dec 2, 2021B of A SecuritiesUnderperform—
Dec 1, 2021HC Wainwright & Co.Neutral—
Sep 20, 2021HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 14, 2026

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of

Benzinga · Aug 14, 2026

BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY

BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By